Liminal BioSciences (LMNL) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Liminal BioSciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LMNL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LMNL, but not buy additional shares or sell existing shares.
View LMNL analyst ratings or view top-rated stocks.

Liminal BioSciences' stock was trading at $3.25 at the beginning of the year. Since then, LMNL stock has increased by 161.5% and is now trading at $8.50.
View the best growth stocks for 2023 here.

Liminal BioSciences saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 300 shares, a decline of 50.0% from the August 15th total of 600 shares. Based on an average trading volume of 20,700 shares, the short-interest ratio is currently 0.0 days. Approximately 0.0% of the shares of the stock are sold short.
View Liminal BioSciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our LMNL earnings forecast.

Liminal BioSciences Inc. (NASDAQ:LMNL) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($2.15) earnings per share for the quarter. The company had revenue of $0.08 million for the quarter. Liminal BioSciences had a net margin of 248.35% and a negative trailing twelve-month return on equity of 88.44%.

Liminal BioSciences's stock reverse split on Wednesday, February 1st 2023. The 1-10 reverse split was announced on Wednesday, February 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Liminal BioSciences investors own include ADMA Biologics (ADMA), CNBX Pharmaceuticals (CNBX), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), Aeterna Zentaris (AEZS), American Cannabis (AMMJ), Bionano Genomics (BNGO), Bergio International (BRGO), CBL & Associates Properties (CBL) and Auxly Cannabis Group (CBWTF).

Liminal BioSciences trades on the NASDAQ under the ticker symbol "LMNL."

Shares of LMNL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LMNL stock can currently be purchased for approximately $8.50.

Liminal BioSciences (NASDAQ:LMNL) has a market capitalization of $26.35 million and generates $310,000.00 in revenue each year. The company earns $380,000.00 in net income (profit) each year or $0.29 on an earnings per share basis.

The company employs 251 workers across the globe.

Liminal BioSciences' mailing address is 440 Armand-Frappier Boulevard Suite 300, Laval A8, H7V 4B4. The official website for the company is www.liminalbiosciences.com. The company can be reached via phone at 1-450-781-0115, via email at investor@liminalbiosciences.com, or via fax at 1-450-781-4477.